Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
©2023 The Authors; Published by the American Association for Cancer Research..
Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy response and outcome differences. Histologic transformation to castration-resistant neuroendocrine prostate cancer (CRPC-NE) is associated with distinct epigenetic alterations, including changes in DNA methylation. The current diagnosis of CRPC-NE is challenging and relies on metastatic biopsy. We developed a targeted DNA methylation assay to detect CRPC-NE using plasma cell-free DNA (cfDNA). The assay quantifies tumor content and provides a phenotype evidence score that captures diverse CRPC phenotypes, leveraging regions to inform transcriptional state. We tested the design in independent clinical cohorts (n = 222 plasma samples) and qualified it achieving an AUC > 0.93 for detecting pathology-confirmed CRPC-NE (n = 136). Methylation-defined cfDNA tumor content was associated with clinical outcomes in two prospective phase II clinical trials geared towards aggressive variant CRPC and CRPC-NE. These data support the application of targeted DNA methylation for CRPC-NE detection and patient stratification.
SIGNIFICANCE: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation of a plasma cell-free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively. This article is featured in Selected Articles from This Issue, p. 384.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancer discovery - 14(2024), 3 vom: 01. März, Seite 424-445 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franceschini, Gian Marco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 09.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/2159-8290.CD-23-0754 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366882767 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366882767 | ||
| 003 | DE-627 | ||
| 005 | 20240309232127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-23-0754 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM366882767 | ||
| 035 | |a (NLM)38197680 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franceschini, Gian Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy response and outcome differences. Histologic transformation to castration-resistant neuroendocrine prostate cancer (CRPC-NE) is associated with distinct epigenetic alterations, including changes in DNA methylation. The current diagnosis of CRPC-NE is challenging and relies on metastatic biopsy. We developed a targeted DNA methylation assay to detect CRPC-NE using plasma cell-free DNA (cfDNA). The assay quantifies tumor content and provides a phenotype evidence score that captures diverse CRPC phenotypes, leveraging regions to inform transcriptional state. We tested the design in independent clinical cohorts (n = 222 plasma samples) and qualified it achieving an AUC > 0.93 for detecting pathology-confirmed CRPC-NE (n = 136). Methylation-defined cfDNA tumor content was associated with clinical outcomes in two prospective phase II clinical trials geared towards aggressive variant CRPC and CRPC-NE. These data support the application of targeted DNA methylation for CRPC-NE detection and patient stratification | ||
| 520 | |a SIGNIFICANCE: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation of a plasma cell-free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively. This article is featured in Selected Articles from This Issue, p. 384 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 700 | 1 | |a Quaini, Orsetta |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuno, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Ciani, Yari |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Sheng-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Sigouros, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Rothmann, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Benelli, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Nardella, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Auh, Joonghoon |e verfasserin |4 aut | |
| 700 | 1 | |a Freeman, Dory |e verfasserin |4 aut | |
| 700 | 1 | |a Hanratty, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Adil, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Elemento, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Tagawa, Scott T |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Felix Y |e verfasserin |4 aut | |
| 700 | 1 | |a Caffo, Orazio |e verfasserin |4 aut | |
| 700 | 1 | |a Buttigliero, Consuelo |e verfasserin |4 aut | |
| 700 | 1 | |a Basso, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Peter S |e verfasserin |4 aut | |
| 700 | 1 | |a Corey, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Haffner, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Attard, Gerhardt |e verfasserin |4 aut | |
| 700 | 1 | |a Aparicio, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Demichelis, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Beltran, Himisha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g 14(2024), 3 vom: 01. März, Seite 424-445 |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:424-445 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-23-0754 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 3 |b 01 |c 03 |h 424-445 | ||